Apolipoprotein E ε4 genotype status is not associated with neuroimaging outcomes in a large cohort of HIV+ individuals

Journal of NeuroVirology

Volumn 22, Issue 5, 2016, Pages 607-614

  Cooley, Sarah A ^a   Paul, Robert H ^a,b   Fennema Notestine, Christine ^c   Morgan, Erin E ^c   Vaida, Florin ^c   Deng, Qianqian ^c   Chen, Jie Ashley ^c   Letendre, Scott ^c   Ellis, Ronald ^c   Clifford, David B ^d   Marra, Christina M ^e   Collier, Ann C ^e   Gelman, Benjamin B ^f   McArthur, Justin C ^g   McCutchan, J Allen ^c   Simpson, David M ^h   Morgello, Susan ^h   Grant, Igor ^c   Ances, Beau M ^d  

^a UNIVERSITY OF MISSOURI ST LOUIS   (United States)

^b MISSOURI INSTITUTE OF MENTAL HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d WASHINGTON UNIVERSITY   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h MOUNT SINAI SCHOOL OF MEDICINE   (United States)

ⁱ CHARTER) Group

Author keywords

Brain volumetrics; Genetics; HIV AIDS; Magnetic resonance spectroscopy

Indexed keywords

APOLIPOPROTEIN E4; CHOLINE; CREATINE; GENOMIC DNA; INOSITOL; N ACETYLASPARTIC ACID; ANTINEOPLASTIC AGENT;

ADULT; ALLELE; ARTICLE; BASAL GANGLION; BRAIN SIZE; CEREBROSPINAL FLUID; COHORT ANALYSIS; FEMALE; GRAY MATTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LATERAL BRAIN VENTRICLE; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; SECONDARY ANALYSIS; WHITE MATTER; BLOOD; BRAIN CORTEX; BRAIN VENTRICLE; CEREBELLUM; DIAGNOSTIC IMAGING; GENE EXPRESSION; GENETICS; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; MIDDLE AGED; RISK FACTOR; VIROLOGY;

ADULT; ALLELES; ANTINEOPLASTIC AGENTS; APOLIPOPROTEIN E4; BASAL GANGLIA; CEREBELLUM; CEREBRAL CORTEX; CEREBRAL VENTRICLES; COHORT STUDIES; FEMALE; GENE EXPRESSION; GENOTYPE; GRAY MATTER; HIV INFECTIONS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROIMAGING; RISK FACTORS; WHITE MATTER;

EID: 84961631521     PISSN: 13550284     EISSN: 15382443     Source Type: Journal    
DOI: 10.1007/s13365-016-0434-7     Document Type: Article

References (50)

1. Ances BM, Ortega M, Vaida F, Heaps J, Paul RH (2012) Independent effects of HIV, aging, and HAART on brain volumetric measures. J Acquir Immune Defic Syndr 59:469–477
2. Anderson AM, Fennema-Notestine C, Umlauf A, Taylor MJ, Clifford DB, Marra CM, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Simpson DM, Morgello S, Grant I, Letendre SL, CHARTER Group (2015) CSF biomarkers of monocyte activation and chemotaxis correlate with magnetic resonance spectroscopy metabolites during chronic HIV disease. J Neurovirol 1:9
3. Becker JT, Martinson JJ, Penugonda S, Kingsley L, Molsberry S, Reynolds S, Aronow A, Goodkin K, Levine A, Martin E, Miller EN, Munro CA, Ragin A, Sacktor N (2014) No association between Apoε4 alleles, HIV infection, age, neuropsychological outcome, or death. J Neurovirol 21:24–31
4. Brummel SS, Singh KK, Maihofer AX, Farhad M, Qin M, Fenton T, Nievergelt CM, Spector SA (2016). Associations of genetically determined continental ancestry with CD4+ count and plasma HIV-1 RNA beyond self-reported race and ethnicity. JAIDS, Advance online publication. doi:10.1097/QAI.0000000000000883
5. Burt TD, Agan BK, Marconi VC, He W, Kulkarni H, Mold JE, Cavrois M, Huang Y, Mahley RW, Dolan MJ, McCune JM, Ahuja SK (2008) Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro and the APOE ε4/ε4 genotype accelerates HIV disease progression. PNAS 105:8718–8723
6. Chang L, Andres M, Sadino J, Jiang CS, Nakama H, Miller E, Ernst T (2011) Impact of apolipoprotein E ε4 and HIV on cognition and brain atrophy: antagonistic pleiotropy and premature brain aging. Neuroimage 58:1017–1027
7. Chang L, Jiang C, Cunningham E, Buchthal S, Douet V, Andres M, Ernst T (2014) Effects of APOE ε4, age, and HIV on glial metabolites and cognitive deficits. Neurology 82:2213–2222
8. Cohen RA, Harezlak J, Schifitto G, Hana G, Clark U, Gongvatana A, Paul RH, Taylor M, Thompson P, Alger J, Brown M, Zhong J, Campbell T, Singer E, Daar E, McMahon D, Tso Y, Yiannoutsos CT, Navia B, HIV Neuroimaging Consortium (2010) Effects of nadir CD4 count and duration of human immunodeficiency virus infection on brain volumes in the highly active antiretroviral therapy era. J Neurovirol 16:25–32
9. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261:921–923
10. Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC (2002) Apoliprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol 155:487–495
11. Ernst T, Chang L, Arnold S (2003) Increased glial metabolites predict increased working memory network in HIV brain injury. Neuroimage 19:1686–1693
12. Fennema-Notestine C, Panizzon MS, Thompson WR, Chen CH, Eyler LT, Fischl B, Franz CE, Grant MD, Jak AJ, Jernigan TL, Lyons MJ, Neale MC, Seidman LJ, Tsuang MT, Xian H, Dale AM, Kremen WS (2011) Presence of ApoE ε4 allele associated with thinner frontal cortex in middle age. J Alzheimers Dis 26:49–60
13. Fennema-Notestine C, Ellis RJ, Archibald SL, Jernigan TL, Letendre SL, Notestine RJ, Taylor MJ, Theilmann RJ, Julaton MD, Croteau DJ, Wolfson T, Heaton RK, Gamst AC, Franklin DR Jr, Clifford DB, Collier AC, Gelman BB, Marra C, McArthur JC, McCutchan JA, Morgello S, Simpson DM, Grant I, CHARTER Group (2013) Increases in brain white matter abnormalities and subcortical gray matter are linked to CD4 recovery in HIV infection. J Neurovirol 19:393–401
14. Fujimura JH, Rajagopalan R (2011) Different differences: the use of ‘genetic ancestry’ versus race in biomedical human genetic research. Soc Stud Sci 41:5–30
15. Gongvatana A, Schweinsburg BC, Taylor MJ, Theilmann RJ, Letendre SL, Alhassoon OM, Jacobus J, Woods SP, Jernigan TL, Ellis RJ, Frank LR, Grant I, CHARTER Group (2009) White matter tract injury and cognitive impairment in HIV-infected individuals. J Neurovirol 15:187–195
16. Gongvatana A, Cohen RA, Correia S, Devlin KN, Miles J, Kang H, Ombao H, Navia B, Laidlaw DH, Tashima KT (2011) Clinical contributors to cerebral white matter integrity in HIV-infected individuals. J Neurovirol 17:477–486
17. Harezlak J, Buchthal S, Taylor M, Schifitto G, Zhong J, Daar ES, Alger J, Singer E, Campbell T, Yiannoutsos C, Cohen R, Navia BA, HIV Neuroimaging Consortium (2011) Persistence of HIV-associated cognitive impairment, inflammation and neuronal injury in era of highly active antiretroviral treatment. AIDS 25:625–633
18. Heaps JM, Joska J, Hoare J, Ortega M, Agrawal A, Seedat S, Ances BM, Stein DJ, Paul RH (2012) Neuroimaging markers of human immunodeficiency virus infection in South Africa. J Neurovirol 18:151–156
19. Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Rivera-Mindt M, Vigil OR, Taylor MJ, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I, CHARTER Group (2010) HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 75:2087–2096
20. Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, LeBlanc S, Corkran DB, Woods SP, Collier AC, Marra CM, Morgello S, Mindt MR, Taylor MJ, Marcotte TD, Atkinson JH, Wolfson T, Gelman BB, McArthur JC, Simpson DM, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I (2011) HIV- associated neurocognitive disorder before and during the era of combination antiretroviral therapy: differences in rates, nature and predictors. J Neurovirol 17:3–16
21. Hoare J, Westgarth-Taylor J, Fouche JP, Combrinck M, Spottiswoode B, Stein DJ, Joska JA (2013) Relationship between apolipoprotein E4 genotype and white matter integrity in HIV-positive young adults in South Africa. Eur Arch Psychiatry Clin Neurosci 263:189–195
22. Hulgan T, Samuels DC, Bush W, Ellis RJ, Letendre SL, Heaton RK, Franklin DR, Straub P, Murdock DG, Clifford DB, Collier AC, Gelman BB, Marra CM, McArthur JC, McCutchan JA, Morgello S, Simpson DM, Grant I, Kallianpur AR, CHARTER Study Group (2015) Mitochondrial DNA haplogroups and neurocognitive impairment during HIV infection. Clin Infect Dis 61:1476–1484
23. Jahanshad N, Valcour VG, Nir TM, Kohannim O, Busovaca E, Nicolas K, Thompson PM (2012) Disrupted brain networks in the aging HIV+ population. Brain Connectivity 2:335–344
24. Jernigan TL, Archibald SL, Fennema-Notestine C, Taylor MJ, Teilmann RJ, Julaton MD, Notestine RJ, Wolfson T, Letendre SL, Ellis RJ, Heaton RK, Gamst AC, Franklin DR Jr, Clifford DB, Collier AC, Gelman BB, Marra C, McArthur JC, McCutchan JA, Morgello S, Simpson DM, Grant I, CHARTER Group (2011) Clinical factors related to brain structure in HIV: the CHARTER study. J Neuroviol 17:248–257
25. Joska JA, Combrinck M, Valcour VG, Hoare J, Leisegang F, Mahne AC, Myer L, Stein DJ (2010) Assocation between apolipoprotein E4 genotype and human immunodeficiency virus-associated dementia in younger adults starting antiretroviral therapy in South Africa. J Neurovirol 16:377–383
26. Kallianpur AR, Jia P, Ellis RJ, Zhao Z, Bloss C, Wen W, Marra CM, Hulgan T, Simpson DM, Morgello S, McArthur JC, Clifford DB, Collier AC, Gelman BB, McCutchan JA, Franklin D, Samuels DC, Rosario D, Holzinger E, Murdock DG, Letendre S, Grant I, CHARTER Study Group (2014) Genetic variation in iron metabolism is associated with neuropathic pain and pain severity in HIV-infected patients on antiretroviral therapy. PLoS One 9:e103123
27. Kallianpur AR, Levine AJ (2014) Host genetic factors predisposing to HIV-associated neurocognitive disorder. Curr HIV/AIDS Rep 11:336–352
28. Kuhlmann I, Minihane AM, Huebbe P, Nebel A, Rimbach G (2010) Apolipoprotein E genotype and hepatitis C, HIV and herpes simplex disease risk: a literature review. Lipids Health Dis 9:8
29. Lin K, Taylor MJ, Heaton R, Franklin D, Jernigan T, Fennema-Notestine C, McCutchan A, Atkinson JH, Ellis RJ, McArthur J, Morgello S, Simpson D, Collier AC, Marra C, Gelman B, Clifford D, Grant I, group C (2011) Effects of traumatic brain injury on cognitive functioning and cerebral metabolites in HIV-infected individuals. J Clin Exp Neuropsychol 33:326–334
30. Logue MW, Schu M, Vardarajan BN, Buros J, Green RC, Go RCP, Griffith P, Obisesan TO, Shatz R, Borenstein A, Cupples LA, Lunetta KL, Fallin MD, Baldwin CT, Farrer LA, Multi-Institutional Research on Alzheimer Genetic Epidemiology (MIRAGE) Study Group (2011) A comprehensive genetic association study of Alzheimer disease in African Americans. Arch Neurol 68:1569–1579
31. Martins CAR, Oulhaj A, de Jager CA, Williams JH (2005) APOE alleles predict the rate of cognitive decline in Alzheimer disease. Neurology 65:1888–1893
32. Masters MC, Ances BM (2014) Role of neuroimaging in HIV-associated neurocognitive disorders. Semin Neurol 34:89–102
33. Mersha TB, Abebe T (2015) Self-reported race/ethnicity in the age of genomic research: its potential impact on understanding health disparities. Human Genomics 9:1–15
34. Morgan EE, Woods SP, Letendre SL, Franklin DR, Bloss C, Goate A, Heaton RK, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Ellis RJ, Abramson I, Gamst A, Fennema-Notestine C, Smith DM, Grant I, Vaida F, Clifford DB, CHARTER Group (2013) Apolipoprotein E4 genotype does not increase risk of HIV-associated neurocognitive disorders. J Neurovirol 19:150–16
35. Murrell JR, Price B, Lane KA, Baiyewu O, Gureje O, Ogunniyi A, Unverzagt FW, Smith-Gamble V, Gao S, Hendrie HC, Hall KS (2006) Association of apolipoprotein E genotype and Alzheimer disease in African Americans. JAMA Neurology 63:431–434
36. Panos SE, Hinkin CH, Singer EJ, Thames AD, Patel SM, Sinsheimer JS, Del Re AC, Gelman BB, Morgello S, Moore DJ, Levine AJ (2013) Apolipoprotein-E genotype and human immunodeficiency virus-associated neurocognitive disorder: the modulating effects of older age and disease severity. Neurobehavioral HIV Medicine 5:11–22
37. Pfefferbaum A, Rogosa DA, Rosenbloom MJ, Chu W, Sassoon SA, Kemper CA, Deresinski S, Rohlfing T, Zahr NM, Sullivan EV (2014) Accelerated aging of selective brain structures in HIV infection: a controlled, longitudinal MRI study. Neurobiol Aging 35:1755–1768
38. Pomara N, Crandall DT, Choi SJ, Johnson G, Lim KO (2001) White matter abnormalities in HIV-1 infection: a diffusion tensor imaging study. Psychiatry Res Neuroimaging 106:15–24
39. Provencher SW (2001) Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed 14:260–264
40. Sacktor N, McDermott MP, Marder K, Schifitto G, Selnes OA, McArthur JC, Stern Y, Albert S, Palumbo D, Kieburtz K, De Marcaida JA, Cohen B, Epstein L (2002) HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 8:136–142
41. Schuff N, Woerner N, Boreta L, Kornfield T, Shaw LM, Trojanowski JQ, Thompson PM, Jack CR Jr, Weiner MW, Alzheimer’s Disease Neuroimaging Initiative (2009) MRI of hippocampal volume loss in early Alzheimer’s disease in relation to ApoE genotype and biomarkers. Brain 132:1067–1077
42. Smith CD, Chebrolu H, Wekstein DR, Schmitt FA, Jicha GA, Cooper G, Markesbery WR (2007) Brain structural alterations before mild cognitive impairment. Neurology 68:1268–1273
43. Spector SA, Singh KK, Gupta S, Cystique LA, Jin H, Letendre S, Schrier R, Wu Z, Hong KX, Yu X, Shi C, Heaton RK, HNRC Group (2010) 195APOE ε4 and MBL-2 O/O genotypes are associated with neurocognitive impairment in HIV-infected plasma donors from Anhui province. China AIDS 24:1471–1479
44. Stebbins GT, Smith CA, Bartt RE, Kessler HA, Adeyemi OM, Martin E, Cox JL, Bammer R, Moseley ME (2007) HIV-associated alterations in normal-appearing white matter: a voxel-wise diffusion tensor imaging study. JAIDS 46:564–573
45. Stout JC, Ellis RJ, Jernigan TL, Archibald SL, Abramson I, Wolfson T, McCutchan JA, Wallace MR, Atkinson JH, Grant I, HIV Neurobehavioral Research Center Group (1998) Progressive cerebral volume loss in human immunodeficiency virus infection: a longitudinal volumetric magnetic resonance imaging study. Neurology 55:161–168
46. Sun B, Abadjian L, Rempel H, Calosing C, Rothlind J, Pulliam L (2010) Peripheral biomarkers do not correlate with cognitive impairment in highly active antiretroviral therapy-treated subjects with human immunodeficiency virus type 1 infection. J Neurovirol 16:115–124
47. Tozzi V, Balestra P, Bellagamba R, Corpolongo A, Salvatori MF, Visco-Comandini U, Vlassi C, GIulianelli M, Galgani S, Antinori A, Narciso P (2007) Persistance of neuropsychological deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J Acquir Immune Defic Syndr 45:174–182
48. Valcour V, Shikuma C, Shiramizu B, Watters M, Poff P, Selnes OA, Grove J, Liu Y, Abdul-Majid KB, Gartner S, Sacktor N (2004) Age, apolipoprotein E4, and the risk of HIV dementia: the Hawaii aging and HIV cohort. J Neuroimmunol 157:197–202
49. Wright EJ, Grund B, Robertson K, Brew BJ, Roediger M, Bain MP, Drummond F, Vjecha MJ, Hoy J, Miller C, de Oliveira AC P, Pumpradit W, Shlay JC, El-Sadr W, Price RW, INSIGHT SMART Study Group (2010) Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology 75:864–873
50. Wright PW, Heaps J, Shimony JS, Thomas JB, Ances BM (2012) The effects of HIV and combination antiretroviral therapy on white matter integrity. AIDS 26:1501–1508